ELOX Eloxx Pharmaceuticals Inc.

9.39
-0.02  -0%
Previous Close 9.41
Open 9.43
Price To Book 10.92
Market Cap 374,273,719
Shares 39,858,756
Volume 24,860
Short Ratio
Av. Daily Volume 86,308

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 data due 2019.
ELX-02
Cystic fibrosis

Latest News

  1. Eloxx Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
  2. Eloxx Pharmaceuticals Announces Pricing of $30.0 Million Public Offering of Common Stock
  3. The Daily Biotech Pulse: DiaMedica Reports Positive Data For Chronic Kidney Disease Drug, Eloxx Offering, IPO Deluge
  4. Eloxx Pharmaceuticals Announces Proposed Public Offering of Common Stock
  5. Why Advanced Micro Devices, Ciena, and Eloxx Pharmaceuticals Jumped Today
  6. Eloxx Pharma Says ELX-02 Data Showed Increases In Key Metric
  7. Investors Who Bought Eloxx Pharmaceuticals (NASDAQ:ELOX) Shares A Year Ago Are Now Down 36%
  8. SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Eloxx Pharmaceuticals, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors
  9. Edited Transcript of ELOX earnings conference call or presentation 9-May-19 12:30pm GMT
  10. Eloxx Pharmaceuticals, Inc. (ELOX) Q1 2019 Earnings Call Transcript
  11. Eloxx Pharmaceuticals Reports First Quarter 2019 Financial and Operating Results and Provides Business Update
  12. Eloxx Pharmaceuticals Presents Positive New Data at the Association for Research in Vision and Ophthalmology “ARVO” 2019 Annual Meeting
  13. Eloxx Pharmaceuticals to Report First Quarter 2019 Financial Results and Provide Business Update on May 9, 2019
  14. Eloxx Pharmaceuticals to Participate in the 2019 5th Annual SunTrust Robinson Humphrey (STRH) Life Sciences Summit on May 7, 2019
  15. SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Breaches of Fiduciary Duty by the Board of Directors of Eloxx Pharmaceuticals, Inc.
  16. Eloxx Pharmaceuticals Presents Positive New Data for Lead Investigational Drug, ELX-02, at the European Cystic Fibrosis Society (ECFS) Basic Science Conference
  17. Proteostasis Plunges on Weak Data From Cystic Fibrosis Study
  18. Eloxx Pharmaceuticals to Present at the Guggenheim Rare Disease & Genomic Medicines Day on April 2, 2019
  19. Edited Transcript of ELOX earnings conference call or presentation 8-Mar-19 1:00pm GMT